Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma
For BCLC-C HCC patients, TACE may significantly increase the therapeutic effectiveness of camrelizumab-rivoceranib without increasing the risk of camrelizumab-rivoceranib-related complications.
Authors
- Xin Lü (ORCID: https://orcid.org/0000-0002-9692-4886)
- Jintao Huang (ORCID: https://orcid.org/0000-0003-3703-0468)
- Wenjie Zhou (ORCID: https://orcid.org/0000-0001-9407-3494)
- Fuan Wang (ORCID: https://orcid.org/0000-0002-3063-2485)
- Di Hu (ORCID: https://orcid.org/0000-0001-7876-3049)
- Xin Hong (ORCID: https://orcid.org/0000-0002-7202-6969)
- Xiaoli Zhu (ORCID: https://orcid.org/0000-0003-0998-0124)
- Peng-Hua Lv (ORCID: https://orcid.org/0009-0006-6406-4363)
Institutions
- Xuzhou Central Hospital (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/jhc.s494520
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Government of Jiangsu Province
- Soochow University